We report the isolation of cDNAs encoding protein tyrosine phosphatases (PTPs) from highly purified hematopoietic stem cell populations. One such cDNA encodes a novel PTP, designated fetal liver phosphatase 1 (FLPI), which consists of one PTP domain followed by a carboxy terminal domain of 160 amino acids. Northern blot and in situ hybridization analysis showed that expression of FLPl mRNA is restricted t o thymus in 15.5-day-old and 17.5-day-old mouse embryos and t o kidney and hematopoietic tissues in adult mice. Furthermore, polymerase chain reaction-based analysis shows that FLPI is expressed in hematopoietic stem cells as well as in more mature hematopoietic cells. Peptide antisera against FLPI immunoprecipitated a 48-kD protein that is localized in the nuclei of Ba/F3 lymphoid cells. We have analyzed the effects of overexpressing either wild-type FLPI or a function-HE HEMATOPOIETIC system continuously produces at least eight different blood lineages.',' At the center of this system is a population of hematopoietic stem cells that can both self-renew and produce committed progenitors for all blood cell lineages. Traditionally, hematopoietic stem cells have been studied as activities either by transplantation contexts or in complex in vitro culture systems. Recently, efforts in a number of laboratories have yielded procedures for the purification of stem cells from adult bone marrow and fetal liver.'.' Thus, it has become possible directly to analyze the mechanisms that control stem cell behavior and identify the molecules that regulate self-renewal and commitment decisions.
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ally inactive mutant of FLPl in hematopoietic cells. In the progenitor K562 cell line, cells ectopically expressing functional FLPI differentiated normally t o megakaryocytes after induction with tetradecanoyl phorbol acetate (TPA). In contrast, when K562 transfectants expressing an inactive mutant FLPI protein were treated with TPA, the characteristic cell spreading and substrate adhesion that accompany megakaryocytic differentiation did not occur. We show that, in these cells, the induction of the differentiation marker all& is not affected. However, both constitutive and TPA-induced expression of a2 integrin, a late megakaryocytic marker, are inhibited. These results suggest that the expression of an inactive form of FLPI affects late signaling events of K562 megakaryocytic differentiation. 0 1996 by The American Society of Hematology.
least one catalytic domain of approximately 250 amino acids that is characterized by the conserved signature motif (I/ V)HCXAGXGR(S/T)G. Within this sequence there is an invariant cysteine residue essential for catalytic activity. The overall structure of receptor-like PTPs contains an intracellular segment with one or two phosphatase domains, a single transmembrane domain, and a variable extracellular segment with putative ligand binding activity. Intracellular PTPs possess a single catalytic domain flanked at either the amino or carboxy terminus by unrelated sequences of variable length. Some of these noncatalytic sequences include Src homology 2 (SH2) domains; segments of homology to the cytoskeletal protein band 4.1 or to lipid binding proteins; motifs that direct association with intracellular membranes; and sequences rich in proline, serine, threonine, and acidic residues (PEST sequences)." ' Despite the large number of PTPs identified, relatively little is known about their biologic roles and mechanisms of action. Two of the best studied WPs, the cytoplasmic SHPl (also called HCP, PTPlC, or SH-PTP1) and the receptorlike CD45, are predominantly expressed in hematopoietic tissues and are known to play pivotal roles in hematopoiesis,~?-~4 Naturally occurring mutations in the SHPl gene are the cause of the severe hematopoietic disorder in motheaten and gene-targeted mutations in CD45 block T-cell maturation. I5 Because PTPs reverse the action of PTKs, including growth factor receptors and oncogene products that stimulate proliferation, it may be predicted that they transmit growthinhibitory signals. Consistent with this idea is the function of SHPl , which is known to downmodulate signals mediated by interleukin-3 (IL-3),I6 erythr~poietin,'~ interferon," Bcell antigen receptor," and CD22.'" Alternatively, PTPs may induce growth. This has been shown in the case of CD45, which is a positive regulator in antigen-stimulated proliferation of T lymphocytes.13 Other PTPs are known to have roles in processes other than cell proliferation. Examples of these are PTPK and PTPp, two receptor-like proteins implicated in regulating cell adhesion,"." and PTP-BAS, an intracellular PTP that inhibits apoptotic signals mediated by the FAS re~eptor.'~ For many PTPs that have unique structural features or that, like the PEST-containing PTPs, constitute subfamilies with no identifiable functional motifs, the biologic functions still remain largely unknown.
Several PTPs have already been identified in hematopoietic ~e l l s . *~-~~ However, the functional roles of these enzymes in stem cell biology are unclear. We report the identification of PTPs expressed in highly purified stem cell populations using a polymerase chain reaction (PCR) cloning approach. Thirteen distinct PTP sequences were identified. Expression patterns in hematopoietic stem cells, pluripotent progenitors, and mature hematopoietic populations have been analyzed. One novel PTP, designated fetal liver phosphatase 1 (FLPl), has been characterized. FLPl is a nuclear protein with structural similarities to PEST-containing PTPs. It is primarily expressed in primitive and more mature hematopoietic cells. We have analyzed the effects of overexpressing either wildtype FLPl or a functionally inactive mutant of FLPl in several hematopoietic cell lines. Deregulated expression of a catalytically inactive mutant of FLPl in hematopoietic progenitor K562 cells inhibits cell spreading and substrate adhesion during in vitro megakaryocytic differentiation. One mechanism for this effect might be a downregulation of a2 integrin expression and inhibition of a* integrin induction during the differentiation process.
MATERIALS AND METHODS
Cell purijkation. C57BL/6 mice were used in all experiments. Stem cell purifications have been described p r e v i o~s l y . '~~~~~~ In brief, midgestation (day-14) fetal liver cells were fractionated into AA4.1 positive by immunopanning. The cells were stained with fluorescein isothiocyanate (F1TC)-labeled lineage (Lin) cocktail (anti-Gr-l, Mac-l, B220, CD3, CD4, CD5, CD8, and TER-I 19), phycoerythrin (PE)-labeled anti-LybA/E (Ly6A), and biotinylated anti-c-Kit receptor followed by streptavidin-APC (Molecular Probes, Eugene, OR). For bone marrow, mononuclear cells were first fractionated by a Ficoll density gradient (< 1.007). and lineage negative or low staining cells (Lin"'") were obtained by magnetic separation with antirat IgG-coated magnetic beads (Dynalab, Rochester, NY) after staining with an FITC-Lin cocktail. The cells were further stained with PE-anti-Ly6A and biotinylated anti-c-Kit. Yolk sac cells from day-9 fetuses were separated by discontinuous gradient of Percoll (< 1.077). Nonadherent cells were immunopanned with AA4.1 antibody and stained with FITC-labeled wheat germ hemaglutinin (FITC-WGA; Sigma, St Louis, MO). For purifications three-color analysis and sorting were performed using an Epics 753 dye laser (Coulter, Hialeah, FL) flow cytometer. All antibodies were purchased from Pharmingen (San Diego, CA) except TER-l19 (a gift of Dr T. Kina, Kyoto University, Kyoto, Japan).
Identification of PTP cDNAs from fetal liver hematopoietic stem cells and PCR expression analysis. Preparation of total RNA from purified AA4.1f, Lin"'", c-Kit+, Sca' fetal liver cells was performed as de~cribed.~' Synthesis of cDNA was performed using Superscript I1 RNase H-reverse transcriptase (GIBCO BRL, Grand Island, NY) and oligo(dT) primer. Purified cDNA was amplified with A and B degenerate PTP primers as described by Matthews et al.25 The cycling parameters were 94°C for 30 seconds, 37°C for 30 seconds, and 72°C for 1 minute. In general, 60 cycles of amplification with the addition of primers and other components at midpoint were performed. Amplified cDNAs with sizes around 300 bp were subcloned into psportl (GIBCO BRL) through Kpn I and Xba I sites incorporated into the oligonucleotides. Bacterial transformants were screened for the presence of the appropriately sized inserts and random clones were chosen and sequenced. Sequences were compared with the EMBO/GenBank data base. Individual clones corresponding to PTPs were pooled and used as probes for sequentially screening a total of 1,300 colonies. For PCR expression analysis, total RNA from fetal liver, yolk sac, and bone marrow cell subpopulations was used for cDNA synthesis using oligo(dT) primer and PCR amplification with degenerate PTP primers. Cycling parameters were 1 minute at 9 4 T , 2 minutes at 42"C, and 3 minutes at 72°C for 48 cycles. Ten percent of the reaction mixtures were electrophoresed on 1.5% agarose gels, Southern blotted, and hybridized to "P-labeled DNA probes corresponding to the different PTP cDNAs isolated from fetal liver stem cells. Amplified cDNAs were normalized and controls for contamination were included in all amplifications. Results were always verified using independently synthesized cDNA templates. The expression patterns for FLPI, PTPP, and DEP-I were corroborated by Southern blot on DNAs from cDNA libraries of different hematopoietic populations.
Library construction and characterization of FLPI cDNA. Fetal liver AA4.1+ cells were obtained from a large number of day-l4 mouse fetuses. RNA from these cells was purified by the guanidinium-thiocyanate-CsCI gradient method and poly(A)+ RNA obtained by standard column protocols. For cDNA synthesis and cloning into the plasmid psportl, we used a Superscript Plasmid System kit (GIBCO BRL). The resulting directional library had an average insert size of 1 to 2 kb and an initial complexity of 5 X 10' clones. Two million recombinant clones of this library were screened with the 250-bp PCR fragment encompassing part of the FLPl catalytic domain. Two cDNA clones encoding for amino acid positions 98 to 452 and extending to the 3' end of the mRNA were isolated. Antisense oligonucleotides corresponding to nucleotide positions 414 to 440 and 504 to 528 were used as gene-specific primers to extend the cloned cDNA in the 5' direction by using the 5"Aplifinder RACE Kit (Clontech, Palo Alto, CA). The template for the amplifications was 5"RACE-Ready kidney cDNA (Clontech). Independently amplified cDNA fragments were sequenced and two contiguous sequences of 1,560 bp (FLPIA) and 1,478 bp (FLPlB) were obtained. The authenticity of these cDNA sequences was further confirmed by PCR with primers corresponding to nucleotide positions I O to 36 and 1515 to 1540, using as templates cDNAs from kidney and fetal liver AA4.1+ cells. All DNAs were sequenced on both strands. The FLPl cDNA sequence is under GenBank accession number U52523. The program PEST-FIND used for the search of PEST sequences was a kind gift of Dr M. Rechsteiner (University of Utah, Salt Lake City, UT).
Northern blot analysis und in situ hybridization. Twenty micrograms of total RNAs, isolated from a range of adult mouse tissues or cells lines by the method of Chomczynski and Sacchi," were separated on formaldehyde-agarose gels and transferred to nylon membranes. Hybridization and washing conditions were as described. 32 The probe fragment encompassed amino acid positions 98 to 235. For comparison, filters were striped and rehybridized with a @-actin probe. For in situ hybridization studies, sense and antisense '3P-labeled probes were synthesized by standard protocols from a pBlueScript (Stratagene, La Jolla, CA) plasmid containing a FLPI cDNA fragment (nucleotides 1217 to 1373). As a positive control, we used the pKLS4 plasmid, which contains a cDNA fragment of the mouse Grb2 protein (kindly provided by K. The immunoprecipitates were dissolved in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer and fractionated in 8% acrylamide gels. Western blotting was performed by transferring proteins onto nitrocellulose membranes using a Milliblot-SDE transfer system (Millipore, Bedford, MA). Membranes were incubated with the appropriate antibody in 5% bovine serum albumin, TrisCl (pH 8.0), 0.9% NaCI. When polyclonal antibodies were used, immunoblots were subsequently incubated with '2sI-protein A and autoradiographed with intensifying screens at -70°C. Blots incubated with anti-a-tubulin and anti-a, integrin monoclonal antibodies were developed using the enhanced chemiluminescence Western blotting (immunoblotting) system (Amersham, Arlington Heights, Cell culture and DNA transfections. U562 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum plus antibiotics. The murine IL-3-dependent cell line B e 3 was maintained in RPMI 1640 supplemented with 10% fetal calf serum and 10% Wehi-3B conditioned medium. The expression plasmids contained the intact FLPlA or mutant FLPIB-CS cDNA sequences cloned in the pBabe retroviral expression vector.3h The single amino acid mutation (C to S) in the FLPlA and FLPlB cDNAs was generated using the Altered Sites I1 in vitro mutagenesis kit (Promega, Madison, WI). K562 and Ba/F3 cells were transfected by electroporation. In brief, 2 X IOh cells were resuspended in 0.4 mL of culturing media and 20 pg of pBabe-FLPIA, pBabe-FLPlA-CS, or pBabe-FLPIB-CS linearized by digestion with Sca I and 1 pg of HindIII-IL). digested pGKneo were added to the cell suspension. Cells were exposed to a 260-V pulse with a capacitance of 960 pF using a Gene Pulser electroporator (Bio-Rad, Melville. NY). After a growing period of 24 hours in their optimal medium, transfected cells were transferred to microtiter plates and selected in G418 (0.8 mg/mL; GIBCO). After 2 weeks, the cells were expanded as independent pools. Single-cell clones were obtained by limiting dilution and analyzed for protein expression.
Determination ofPTP activity. Enzymatic activity of FLPl immunoprecipitates from K562 clones overexpressing FLPl A, FLPl A-CS, and FLPIB-CS was determined using a malachite green microtiter-plate assay." Cellular lysates from 50 X IOh cells were incubated with EN12 antibody and immunoprecipitates were collected and washed as described above. Enzyme reactions were performed in Y6-well plates in a final volume of 25 pL. Substrates included tyrosinephosphorylated peptides TSTEPQpYQPGENL and RRLIEDAEp-YAARG (Upstate Biotechnology, Lake Placid, NY), corresponding to the C-terminal regulatory and autophosphorylation sites of c-src. respectively. The immunoprecipitates bound to protein A-Sepharoae beads were incubated at 37°C with 0.25 mmol/L peptide in 150 mmol/L Tris-C1 (pH 7.4), 0.16% 2-mercaptoethanol. Reactions were performed for 10 to 15 minutes, were terminated by the addition of malachite green solution (Upstate Biotechnology), and were incubated for 15 minutes before the measurement of absorbance at 630 nm. Time dependency was determined to ascertain that times of incubation fell within the linear range of the time course.
Anulysis of K562 cellular differentiation. Erythroid differentiation was induced by adjusting logarithmetically growing cells to 36 pmol/L cytosine arabinoside (AraC). After 5 days, the cells were stained with benzidine solution as described." Megakaryocytic differentiation was induced with 0.17 pmol/L tetradecanoyl phorbol acetate (TPA) and assessed by cellular morphology, cytochemical staining, cellular adherence, Western blot analysis with a, integrin antibody (Chemicon, Temecula, CA), and flow cytometry analysis with FITC-labeled CD41 b (a&) and CD4Yb (a? integrin) antibodies (Pharmingen).
RESULTS
Identi$cation of PTP cDNAs expressed in hematopoietic stem cells. To identify PTPs expressed in murine hematopoietic stem cells, we used PCR amplification with degenerate oligonucleotides derived from conserved sequences in the tyrosine phosphatase domains. Template cDNA was prepared from AA4.1', Lin"'", c-Kit+, Sca-l' cells isolated from midgestation (day-14) fetal liver. This subpopulation is highly enriched in multipotent stedprogenitor activities.' Analysis of 1,300 PCR-amplified cDNA fragments showed 13 different sequences that contained the hallmark residues found in all PTPs (Table 1 ). Database comparison showed that 8 of the isolated PTP fragments were identical to the murine cDNAs for LRP,79 HPTPP,4" CD45,4' SHPl PTPT-9,42 PTP 1B,4' MEG2,# and PTP-BAS. 45 Two other sequences showed high homology at the amino acid level (88% and 9 1 %) to the PTP domains of human HePTp6 and DEPrespectively, and therefore are likely to be their murine homologues. Similarly, two clones, PTPc-1 and PTPc-2, are likely to be related to PTPE because they are 85% and 86% homologous to the first phosphatase domain of human PTPE.~" One of the identified PTPs corresponded to a novel sequence, and was named FLPl.
The expression patterns of all the PTP cDNAs isolated 
PTP cDNA sequences were PCR-amplified using degenerate oligonucleotides specific for the conserved sequences of PTP catalytic domains. The DNA template was cDNA from AA4.1', Lin-n", Sca-l', cKit+ fetal liver cell populations.
Percentage numbers are based on the relative abundance of each PTP sequence calculated by differential hybridization screening of a library of 1,300 individual PCR-derived colonies.
from fetal liver stem cells were analyzed in different hematopoietic populations. Our stem cell enrichment procedure delineates four cell subpopulations: AA4. l + ;
AA4. l -; AA4. l ', Lin"'", c-Kit', Sca-l'; and AA4.1', Lin-"", c-Kit+, Sca-I -.
As previously described,.' the AA4. l', Lin-"", c-Kit', Sca-l subpopulation contains the bulk of long-term reconstituting hematopoietic stem cells and multipotent progenitors. Progenitor cells are also found in the AA4.1+ and AA4.1'. Lin-", c-Kit', Sca-I -subpopulations. More mature progenitors are present in the AA4.1-subpopulation. Two other sources of hematopoietic stem cells are adult bone marrow and day-9 yolk sac. Bone marrow hematopoietic stem cells are defined as Lin-"O, c-Kit', Sca-l'. As for fetal liver, the Lin-"", cKit', Sca-l-subpopulation contains more mature progenitors. 29 In day-9 yolk sac, the hematopoietic stem cells and multipotential progenitors were enriched in a cell population defined as AA4.1', WGA'", as previously described.*' Because of the small amounts of RNA obtained from these cell subpopulations, the expression of all the different PTPs was estimated by reverse transcriptase-PCR (RT-PCR) followed by Southern blot hybridization using the PCR-derived cDNA fragments as probes. Figure 1 shows representative examples of patterns of expression for some of the PTPs. The RT-PCR analysis showed that DEP-I is expressed in stem cell subpopulations from bone marrow, but is barely detectable in yolk sac and fetal liver stem cell subpopulations (Fig 1) . Two PTPs, PTPT-9 (Fig 1) and PTP-BAS, were found to be expressed in the stem cell subpopulations from fetal liver and bone marrow but not from yolk sac. The remaining PTPs were detected in stem cell subpopulations from all three tissue sources. Moreover, PTPP, MEG2. and FLPl showed differential patterns of expression. As shown in Fig 1, PTPP mRNA is present in all cell fractions analyzed, but its relative levels appear to be much higher in the fetal liver stem cell subpopulation (AA4.1'. Lin-"", c-Kit+, Sca-l') than in the AA4.1+, Lin-"", c-Kit', Sca-I-, which lacks long-term hematopoietic stem cells. MEG2 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From cell subpopulations isolated from fetal liver and bone marrow (Fig l) . However, in yolk sac, MEG2 and FLPl cDNAs are detected in AA4.1+, WGAb", which contains stedprogenitor cells but not in AA4. l', WGA", which is lacking in stem cells and primitive progenitor cells.
The predicted amino-acid sequence of FLPl cDNA. The expression of FLPl in hematopoietic stem cell subpopulations from both fetal and adult sources and its cell-lineage specificity in yolk sac prompted us to further analyze this PTP. To determine the primary structure of FLPl, a mouse cDNA library (constructed from day-l4 fetal liver AA4.1+ cells) was screened with the PCR fragment corresponding to the FLPl catalytic domain. Because cDNA clones initially isolated from this library did not contain the complete coding sequence, overlapping cDNA fragments corresponding to the 5'-end of the cDNA were isolated by PCR. To this purpose, oligonucleotides corresponding to FLPl nucleotide positions 414 to 440 and 504 to 528 were used as gene specific primers to extend the cloned cDNA in the 5' direction, using as templates cDNAs from kidney and fetal liver AA4.1+ cells. The intact sequeace of FLPl (GenBank accession no. U52523) is shown in Fig 2. After sequencing several independently amplified cDNA fragments, we identified two distinct cDNAs, FLPlA and FLPIB, that differed by the presence (FLPlA) or absence (FLPIB) of a sequence in the open reading frame encoding a 24-amino acid stretch after residue at position 8 (Fig 2) . Although the sequence surrounding the putative initiator codon at nucleotide positions 64-66 does not conform well to the Kozak consensus sequence, there is a purine at position -3 that is an important requirement for an initiation site. 48 The predicted sizes for the proteins encoded by the FLPl A and FLPlB cDNAs are 452 and 428 amino acids, respectively. Analysis of both sequences indicated the presence of a PTP domain located near the amino terminus, from residues 48 to 292, followed by a 160 amino acid-long carboxy terminal tail. The 66-bp 5"untranslated region contains an in-frame stop codon at positions 13-15 and the 144-bp 3"untranslated region contains a consensus polyadenylation signal. Comparison of the FLPl cDNAs with those available in the database showed an almost identical sequence (GenBank accession no. U49853) that was recently identified by another group from hematopoietic progenitor cells. This cDNA is 99.8% identical at the nucleotide level to our FLPlA cDNA, and encodes for a 453 amino acid protein that is 98% identical to the FLPlA protein. Differences in both sequences include an amino acid change in position 1 1 and a stretch of amino acids (positions 362-367 of the FLPl sequence and 362-368 of the hematopoietic progenitor sequence) that are different in both cDNAs. At the present time, the authenticity andor significance of these differences are unknown.
Amino-acid sequence comparison of the catalytic domain with other PTPs showed that the closest relationships are to PTP-PEST (also named P19 or PTP G1; 5 1%) and PEP (47%). PTP-PEST and PEP are intracellular PTPs characterized by the presence of one catalytic domain at the aminoterminus linked to a large carboxy-terminal region that is rich in PEST s e q u e n~e s .~~.~"~~ The amino acid sequence alignment of FLPI, PTP-PEST, and PEP with the structurally unrelated HCP and CD45 (Fig 3) shows that FLPl , PTP-PEST, and PEP constitute a separate subfamily of PTPs. PEP has recently been described to localize in the nucleus.'' A carboxy-terminal sequence of 12 amino acids has been shown both necessary and sufficient for nuclear localization. A very similar sequence is found at the extreme carboxy terminus of PTP-PEST. Comparison of the noncatalytic sequences of FLPl with sequences in the data base showed no significant similarities except in the last 22 carboxy-terminal residues (underlined in Fig 2) , which are 68% identical to the carboxy-terminal sequence of PTP-PEST. However, FLPl does not have subdomains containing PEST sequences found in PTP-PEST and PEP. The functions of PTP-PEST and PEP are unknown, but a recent report described that the phosphatase activity of PTP-PEST can be regulated by phosphorylation on Ser 39.j4 Interestingly, this Ser residue is conserved in the same location in both PEP and FLPl sequences (Fig 3) .
Expression of FLPl in mouse embryos, adult tissues, and cell lines. The expression of FLPl in tissues of adult mice was examined by Northern blot analysis. As shown in Fig  4A , a major transcript of 1.7 kb is readily detected in bone marrow, kidney, spleen, and thymus. This restricted distribution is reminiscent of HCP, which is expressed in hematopoietic tissues, kidney, and lung.25 To examine the levels of FLPl mRNA in different hematopoietic lineages, lymphoid and myeloid cell lines were analyzed (Fig 4B) . FLP I expression is relatively high in the thymoma line AKRl , the pro-B-cell line BdF3, the pre-B-cell line 702/3, the B-cell lymphoma WEHI-279, the leukemia line M2.4, and the macrophage lines RAW309 and WEHI-3. In contrast, FLPl is expressed at very low levels in the leukemia line D2N, the myeloblast line MI, and the mastocytoma P8 15 and is virtually undetectable in NIH 3T3 fibroblasts. In addition to the 1.7-kb mRNA, a smaller FLPl mRNA species of 1.6 kb is present in the 702/3 and MI cell lines.
To examine the spatial distribution of FLPl mRNA in embryonic tissues, we performed in situ hybridization on sections from 15.5-day-old (E15.5) and 17.5-day-old (E17.5) mouse embryos. As shown in Fig 5A, FLPl mRNA is readily detected in E15.5 embryonic thymus and nasal epithelium. Much weaker signals are observed in kidney, liver, and intestine. Analysis of E17.5 embryos showed that FLPl expression continues at high levels in the thymus (Fig 5B) . Close examination of the in situ hybridizations shows that in both E15.5 and E17.5 thymus the FLPl transcript is present at highest levels in cortical thymocytes (Fig 5C and D) .
Subcellular localization of FLPl protein.
To identify the FLPl protein in vivo, we generated polyclonal antibodies against a bacterial GST fusion protein containing residues 183 to 405 of the predicted FLPl gene product. A rabbit antiserum elicited against this fusion protein efficiently immunoprecipitates the FLPl polypeptide when transiently expressed in COS cells (data not shown). Moreover, this antibody specifically recognizes a single 48-kD protein in lysates of pro-B BdF3 and pre-B 70Z/3 cells (Fig 6A) , which is equivalent with the molecular weight predicted from the 
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pLp1 ------ fied as an inhibitory phosphorydeduced FLPIA amino acid sequence. The FLPl protein displays the same electrophoretic mobility in COS cells and in four mouse hematopoietic cell lines, the T-cell line EL4, the myeloblast line MI (Fig OB) , the mastocytoma line P8 15, and the macrophage line RAW309 (data not shown). However, in the human leukemia line KS62, the FLPl polypeptide shows a slightly smaller (45 kD) molecular weight, suggesting that, in these cells, the protein exists either as a different-size isoform or undergoes distinct postranslational modifications. Because the FLPl sequence contains a putative nuclear localization signal similar to those present in PTP-PEST and PEP, we examined the subcellular localization of the FLPl protein by immunoprecipitation and Western blot analysis. As a control, the nuclear and cytoplasmic fractions were incubated with antibodies against a-tubulin, a cytoplasmic protein. As shown in Fig 6C, Treatment of K562 cells with hemin or AraC can induce erythroid differentiation. In contrast, treatment with TPA leads to a macrophage-like morphology while inducing the expression of proteins associated with megakaryocytes. We first determined the pattern of FLPl expression during differentiation of K562 cells by immunoblotlot analysis on cellular extracts nontreated and treated with AraC or TPA. As shown in Fig 7, the FLPl protein is readily detectable in untreated cells and continues to be expressed during erythroid and myeloid differentiation. A slight increase in FLPl levels is observed after 7 days of treatment with TPA.
We generated KS62 clones overexpressing either the FLPl protein (FLPI-A) or nonfunctional mutants of FLPl derived by site-directed mutagenesis of the active Cys residue to a Ser residue (FLPIA-CS and FLPI-B-CS; Fig 8A) . Retroviral expression vectors were constructed and electroporated with pGKneo into K562 cells. Individual clones were examined for protein expression, and four clones expressing high levels of FLPl A protein, four clones expressing high levels of FLPl A-CS protein, and four clones expressing high levels of FLPlB-CS protein (Fig 8B) were selected for further studies.
The PTP activity of the exogenous and endogenous proteins in the K562 transfectants was investigated by in vitro PTP assay. FLPIA, FLPIA-CS, or FLPIB-CS were coimmunoprecipitated with endogenous FLPl and incubated with a synthetic phosphotyrosine peptide containing the C-terminal phosphorylation site of c-src. Dephosphorylation was allowed to proceed and the extent of PTP activity was determined using a malachite green colorimetric assay. As shown in Fig 8C, immunoprecipitates from the K562-FLPIA transfectants show a fourfold to fivefold increase in PTP activity relative to parental K562 cells. In contrast, the PTP activity in immunoprecipitates from KS62 containing the mutants FLPIA-CS or FLPIB-CS is equivalent to the background levels observed for the parental K562 line. These results indicate that the K562-FLPI A clones express functional FLPl protein and that, as previously reported for other Treatment of K562 cells with TPA increases cell-cell and cell-substrate adhesion and induces the expression of membrane proteins associated with the megakaryocyte lineage. To investigate whether K562-FLPI A, K562-FLPI A-CS, and K562-FLP I B-CS clones are able to differentiate along this pathway, we analyzed morphologic, cytochemical, and cell adhesion changes after TPA treatment. The addition of TPA to parental K562 and K562-FLPIA cells caused an immediate growth arrest and differentiation to morphologically recognizable megakaryocytes, with approximately 50% to 60% of the cells being adherent. over the course of 5 to 7 days (Fig 9) . Cells from all the clones overexpressing the mutants FLPIA-CS and FLPlB-CS also undergo growth arrest and initial changes consistent with megakaryocyte morphology, but, in contrast to parental and wild-type FLPIA-transfected K562 cells, they contain considerably lower percentages (5% to 10%) of adherent cells. Moreover, they formed large cellular aggregates after TPA treatment. These results suggest that the expression of a catallytically inactive FLPl protein negatively affects the adhesion properties of K562 cells differentiated along the megakaryocytic pathway. To investigate this further, we analyzed the modulation of the major platelet integrin (YllhP?, a protein complex considered an early marker of megakaryocytic differentiation. whose expression in K562 cells is markedly increased between days 1 and 3 of exposure to phorbol ester." Figure 10A shows the results of flow cytometry analysis of (Yl& expression before and after 3 days of TPA treatment. Cell-surface expression of (Yl& increased 15-to 30-fold in parental K562 cells and in all transfectant clones, indicating that induction of a& is not affected by overexpression of wild-type or mutant FLPI. We next analyzed the expression of az integrin. The a2pI integrin complex serves as a cell surface receptor for collagen on platelets and other cells. Elevated expression of a2pI accompanies megakaryocytic differentiation. In K562 cells, the induction of a2 integrin expression, which occurs between 3 and 5 days of exposure to phorbol dibutyrate, seems to be implicated in the final steps of megakaryocyte differentiation." Flow cytometry analysis showed that the levels of az integrin in untreated cells are lower in K562-FLPIA-CS and K562-FLPIB-CS clones than in parental K562 and K562-FLPIA cells. Furthermore, the induction of a2 integrin expression after 4 days of TPA treatment is remarkably higher in the parental line K562 and all K562-FLPI A clones than in the KS62-FLPIA-CS and K562-FLPIB-CS clones (Fig 10B) . Western blot analysis on protein lysates from K562, K562-FLPIA, and K562-FLPI B-CS also showed the decreased ability of cells expressing a catallytically inactive FLPl protein to induce a2 integrin expression (Fig IOC) .
DISCUSSION
The above studies were aimed at identifying the spectrum of PTPs that are expressed in hematopoietic stem cells. A comparable approach was previously successful in our laboratory for the isolation of PTKs from hematopoietic stem cells m.)z . . Twelve known PTP sequences and one novel PTP sequence were identified. Based on previous studies, it was anticipated that cDNA clones for hematopoietic-specific PTPs such as CD45, HCP, or HePTP would be obtained. Other expected cDNAs were PTPs widely expressed or known to be present in hematopoietic cells. These included LRP, PTPe, PTP 1 B, DEP-I , MEG2, PTPT-9, and PTP-BAS. However, it was not expected that the murine homolog of HPTPp would be present at high frequency in our amplified populations. HPTPp is a receptor-like PTP that contains an array of fibronectin type 111 repeats in the extracellular domain. The gene encoding HPTPp was originally cloned from human placenta'" and mouse brain,5x and its pattern of expression in other tissues has not been reported. Interestingly, when we examined the distribution of mouse PTPp in different hematopoietic populations, we found that this PTP is expressed in a fetal liver population highly enriched for stem cells but is hardly detectable in a population that lacks multipotent stem cells. Given that the presence of fibronectin 111 motifs has been related to functions in cell adhesion" and contact inhibition of cell growth,'" PTPP may be a candidate for mediating interactions between hematopoietic stem cells and other cellular or extracellular matrix components of the fetal liver.
The remaining PTPs identified in our screen were found to be expressed in all fetal liver and bone marrow cell populations analyzed. Two PTPs, MEG2 and FLPl, were differentially expressed in yolk sac subpopulations. Both MEG2 and FLPl mRNAs are present in the yolk sac fraction containing stem cells but not in the fraction devoid of stem cells. In this report, we describe the cloning, expression analysis, and functional characterization of FLPI. We show that FLPl RNA is preferentially expressed in day-15.5 and day-17.5 fetal thymus and in a limited number of adult organs, including kidney and hematopoietic tissues. These results suggest that this PTP is likely to have a function regulating tyrosine phosphorylation events specific to hematopoietic cells. Some clues about such function were provided with the characterization of FLPl as an intracellular PTP that contains a short N-terminal domain followed by one PTP domain and a Cterminal segment with a putative nuclear localization signal. Our subcellular fractionation experiments show that the endogenous FLPl protein is localized in the nucleus of BaF3 cells. Two previously identified PTPs, named PEP and PTP-PEST, contain structural motifs and localization signals similar to those found in FLP1, suggesting that these three proteins constitute a separate subfamily of PTPs. PEP is primarily expressed in hematopoietic tissues's and is localized to the nucleus." PTP-PEST is widely distributed and has been recently reported to reside in the ~y t o p l a s m~~~~"~~ The reason for the difference in the subcellular localization of these proteins, which have similar targeting motifs, is unknown, but may reflect the existence of regulatory mechanisms that control their location in a cell-type or activationstate-dependent manner. It is also interesting to note that FLPI, PTP-PEST, and PEP contain unique C-terminal domains with no significant homologies to known sequences or polypeptide motifs. Fuithermore, whereas in PEST and For personal use only. on October 3, 2017. by guest www.bloodjournal.org From PEP the C-terminal noncatalytic domains are approximately 500 amino acids long and contain sequences rich in proline, glutamic acid, serine, and threonine (PEST sequences), in FLPl the C-terminal segment is relatively short (-160 amino acids) and does not contain PEST subdomains. These differences in the C-terminal domains of FLP1, PTP-PEST, and PEP may reflect distinct regulatory mechanisms or substrate specificities. Additionally, because PEST sequences are characteristic of rapidly degraded proteins, the C-terminal domains of PTP-PEST and PEP could be implicated in conferring rapid turnover rates to the proteins. However, both PTP-PEST and PEP have been reported to have long h a l f -l i~e s~~,~~; therefore, the role(s) of their PEST domains remains to be established.
In addition to restriction in expression or confinement to a particular subcellular localization, the functional specificity of PTPs is likely to be controlled by regulation of the PTP enzymatic activity. A regulatory mechanism that modulates the catalytic activity of several PTPs is phosphorylation.60,61 One such PTP is PTP-PEST, which was recently reported to be regulated by serine phosphorylation. A serine residue at position 39 has been identified as a major inhibitory phosphorylation site on PTP-PEST in vivo after protein kinase A (PKA) a~tivati0n.l~ Interestingly, serine residues are conserved in similar locations in FLPl (position 37) and PEP (position 3 9 , although, in the case of FLP1, the serine is not part of a consensus PKA phosphorylation site. Other putative sites of phosphorylation include S47, T57, T172, S319, and T329, which have the hallmarks of protein kinase C (PKC) phosphorylation sites, and SlO, T111, S194, S202, T209, T295, T373, and S413, which possess the minimum requirements for phosphorylation by casein kinase 11. Further experiments are required to resolve whether FLPl is phosphorylated in vivo.
A second regulatory mechanism of FLPl enzymatic activity could be the existence of protein isoforms with sequence differences within or adjacent to the PTP domain. The presence of multiple protein isoforms with variable sequences within the PTP domain has been previously described for other PTPs, including LRP,39 LAR, PTPS, PTPo,~' and PTP-PEST?".5' The functional significance of these differences is not known. In fetal liver and kidney, we found two FLPl cDNAs that differ in the presence or absence of a 24 amino acid insert located in the N-terminal segment of the protein.
Moreover, using PCR, we have identified two other FLPl variants in kidney with different sequences within the PTP domain (unpublished results). Interestingly, one of these variants predicts 29 additional amino acids after position 93, a location where HCP also contains additional residues in comparison to other PTPs (Fig 3) To gain further insight in the FLPl biologic function, we explored whether deregulated FLPlA, FLPlA-CS, or FLPlB-CS protein expression had any effects on erythroid and myeloid differentiation of K562 cells. After treatment with AraC, parental K562 and all transfectant K562-FLPlA, K562-FLPlA-CS, and K562-FLPlB-CS cells underwent growth arrest and induced hemoglobin synthesis at similar levels. This suggests that FLPl is not directly involved in the signaling pathways that couple AraC growth inhibition with erythroid differentiation in K562 cells. Likewise, initial morphologic and cytochemical changes consistent with megakaryocytic differentiation occurred in all transfectants after treatment with TPA. Interestingly, K562 cells expressing FLPlA-CS and FLPlB-CS showed decreases in the spreading and adhesive properties as compared with parental and K562-FLPlA cells. These results suggest that the ectopic expression of a catalytically inactive FLPl protein might be inhibiting the changes in cell adhesion that occur during K562 megakaryocytic differentiation and indicate that this is not an isoform-specific effect. In this respect, we showed that the endogenous and TPA-induced expression levels of a2 integrin, a protein previously shown to be essential for binding of K562 cells to collagen sub~trates,~' are comparatively very low in the K562-FLPlA-CS and K562-FLPlB-CS clones. One explanation for this may be that high levels of FLPl A-CS or FLPlB-CS protein inhibit cellular differentiation. However, this seems unlikely because all K562-FLPl A-CS and K562-FLPlB-CS clones retain their abilities to undergo erythroid differentiation and to induce early megakaryocytic markers, such as the protein complex aIIbP3. The ability of K562-FLPlA-CS and K562-FLPlB-CS cells to undergo morphologic changes and induce early megakaryocytic markers also excludes a direct role for FLPl in the immediate signaling pathways initiated by protein kinase C after activation with TPA. Our results are more consistent with the interpretation that FLPl has a function in late signaling events of K562 megakaryocytic differentiation and that the expression of an inactive form of the FLPl acts in a For personal use only. on October 3, 2017. by guest www.bloodjournal.org From dominant negative manner. Also consistent with a function in the final stages of megakaryocytic differentiation is the fact that FLPl protein levels increase in K562 cells after 7 days of TPA treatment. Because the expression of PTP-PEST is known to be induced during differentiation of P19 cells,5" it could be that FTPs of the FLPl subfamily are generally implicated in late or terminal differentiation events. Alternatively, the effect of the FLPl mutants could be due to an ability to sequester substrates and act in a dominant positive manner, as suggested for similar mutants of other PTPs." Another possible explanation is that FLPl could be involved in the regulation of specific genes, such as the a2 integrin gene, whose expression happens to increase during megakaryocytic differentietion. In this respect, numerous studies have shown that tyrosine phosphorylation events are directly implicated in transcriptional regulation in the interferon and other cytokine-mediated signaling pathways. 64 In summary, our data show that FLPI, a novel PTP isolated from hematopoietic stem cells, is a nuclear PTP with restricted tissue distribution. Moreover, we provide evidence that expression of a nonfunctional FLPl protein can affect late signaling events and downmodulate the levels of a2 integrin during K562 megakaryocytic differentiation. This has important implications for understanding the function of FLPl . Future work will lead to the identification of functionally relevant domains and protein-protein interaction motifs in the FLPl protein and to the functional analysis of FLPl in cellular adhesion and terminal differentiation processes of hematopoietic cells.
